The latest addition to the prestigious CICAD series is a review on inorganic chromium (VI) compounds, assessing the available human health and environmental data and summarising the toxicological studies considered critical for the risk assessment. The main concerns for Cr (VI) relate to its genotoxicity, carcinogenicity and sensitization potential, particularly resulting from occupational exposure. In workers, the cumulative lifetime excess risk of lung cancer is estimated to be 6 in 1000 for exposure to 1 µg Cr (VI)/m3 8 hours/day, 5 days/week for 45 years. For non-cancer effects (on the respiratory tract), tolerable concentrations via inhalation were derived for chromium trioxide/chromic acid and for Cr (VI) salts at  0.005 and 0.03 µg Cr (VI)/m3, respectively. Based on a 2-year study in which mice given sodium dichromate dihydrate in the drinking water showed gastrointestinal effects, an oral tolerable daily intake (TDI) of 0.9 µg Cr (VI)/kg bw was derived for non-cancer effects.

International Programme on Chemical Safety. Concise International Chemical Assessment Document 78: Inorganic chromium (VI) compounds. World Health Organization. Geneva, 2013.


The above item was taken from the October 2013 issue of Toxicology and Regulatory News which is sent automatically to members of bibra (click here for more details).

News Home Guest Write For Us? Contact Us